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Increased uric acid levels have been implicated in the pathogenesis of metabolic syndrome. To examine the mechanisms by which
this occurs, we hypothesized that an increase in heme oxygenase 1, a potent antioxidant gene, will decrease uric acid levels and
adipocyte dysfunction via suppression of ROS and xanthine oxidase (XO) levels. We examined the effect of uric acid on adipogenesis
in human mesenchymal stem cells (MSCs) in the presence and absence of cobalt protoporphyrin (CoPP), an HO-1 inducer, and
tin mesoporphyrin (SnMP), an HO activity inhibitor. Uric acid increased adipogenesis by increasing NADPH oxidase expression
and elevation in the adipogenesis markers C/EBP𝛼, PPAR𝛾, and Mest, while decreasing small lipid droplets and Wnt10b levels. We
treated MSCs with fructose, a fuel source that increases uric acid levels. Our results showed that fructose increased XO expression
as compared to the control and concomitant treatment with CoPP significantly decreased XO expression and uric acid levels. These
beneficial effects of CoPP were reversed by SnMP, supporting a role for HO activity in mediating these effects. These findings
demonstrate that increased levels of HO-1 appear crucial in modulating the phenotype of adipocytes exposed to uric acid and in
downregulating XO and NADPH oxidase levels.

1. Introduction
Obesity is an epidemic that is becoming increasingly more
prevalent, particularly in Western societies. Fructose, a
dietary component, is often implicated in the development
and exacerbation of obesity [1–6]. Much like glucose, fructose is a monosaccharide that is metabolized through the
glycolytic pathway [7, 8]. However, unlike glucose, fructose
is not primarily phosphorylated by hexokinase/glucokinase
in the liver, but rather fructokinase, also known as ketohexokinase (KHK). KHK utilizes ATP to phosphorylate fructose
to fructose-1-phosphate [2, 3]. This step is not regulated by
insulin or fasting; furthermore, it bypasses the regulatory step
in glycolysis catalyzed by phosphofructokinase. Therefore,

unregulated fructose metabolism produces uric acid as a
byproduct through the induction of XO, thereby contributing
to obesity and the potential for metabolic syndrome by
increasing reactive oxygen species (ROS).
We hypothesized, as have others, that one mediator
of fructose-induced symptoms of metabolic syndrome is
uric acid [9–12]. Hyperuricemia is a well-known prelude to
the development of many conditions, including gout and
kidney disease [13]. Uric acid levels, highly predictive of
body mass index (BMI) in humans, are elevated by many
factors, including high purine diets and high fructose diets
[10, 14]. While uric acid is a potent antioxidant, it can be
highly damaging at elevated levels as seen in gout [15].
Ironically, its intracellular effect is to stimulate the production
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of reactive oxygen species [16]. Intracellular uric acid has
multiple origins, one of which is urate transport into cells
through various transporters including URAT1, OAT, and
SLC2A9 [13]. However, another origin of a more problematic
nature is the KHK-dependent ATP depletion during fructose
metabolism, which leads to a dramatic intracellular increase
in purine degradation and uric acid. This pathway accelerates
production of uric acid, as evidenced by diseases that inhibit
purine recovery, such as Lesch-Nyhan syndrome. Uric acid
induces oxidative stress via activation of NADPH oxidase
[16]. NADPH oxidase increases production of O2 − , resulting
in increases in ROS, adipogenesis, insulin resistance, and
inflammation [15, 17]. In addition, uric acid stimulates fructokinase and increases fructose breakdown [18]. This suggests
that hyperuricemia is an indicator of adipocyte dysfunction
in metabolic syndrome, and inducers of uric acid, especially
fructose, may pose a serious threat to adipocyte function.
Imbalances in cellular redox status have been linked to
adipose tissue dysfunction [4, 16]. It has been demonstrated
that an NADPH oxidase inhibitor abolished the augmented
ROS production accompanying adipogenesis in adipocytes
[16, 19]. On the other hand, there is evidence that oxidative
stress may promote adipogenesis via an upregulation of
C/EBP𝛼 and PPAR𝛾 in human bone marrow MSC [2, 20, 21].
The ROS produced by NADPH oxidase go on to activate
the transcriptional factor Peg-1/Mest and induce adipocyte
enlargement [22]. Induction of HO-1 decreases endogenous
ROS and the protective effect of increased HO-1 expression
is ascribed to several factors that include a reduction in
cellular heme, the induction of the iron binding protein
ferritin, and the increased formation of bilirubin, which
efficiently scavenges toxic oxygen species [23]. Induction
of HO-1 expression in vivo and in vitro is associated with
an increase in preadipocytes, a reduction in the number
of enlarged adipocytes, elevated adiponectin secretion, and
an increase in the number of small adipocytes, which are
regarded as “healthy” adipocytes [24]. HO-1 upregulates the
transcriptional proteins 𝛽-catenin and Wnt10b that induce
production of adiponectin, a hormone that keeps adipocytes
small and healthy, and inhibits the activity of PPAR𝛾, a
transcriptional factor that induces adipogenesis [25, 26].
The goal of this study was to determine whether fructoseand uric acid-induced adipocyte dysfunction in MSCderived adipocytes could be ameliorated by suppression
of XO and NADPH oxidase by upregulation of HO-1.
Our results showed that induction of HO-1 gene expression decreased lipid deposition and positive regulators of
adipogenic markers and downregulated the expression of
XO and NADPH oxidase. These findings demonstrate that
increased levels of HO-1 appear crucial in modulating the
phenotype of adipocytes exposed to uric acid and in suppressing markers of adipocyte hyperplasia and inflammation.
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(𝛼-MEM, Invitrogen, Carlsbad, CA) that was supplemented
with 20% FBS and 1% A/A. The cells were transferred into a
75-cm2 flask, cultured in 𝛼-MEM with 20% FBS and 1% A/A,
and maintained at 37∘ C in a 5% CO2 incubator. The medium
was changed after 24 hours and every 2 days thereafter.
Once being 80% confluent, the MSCs were recovered by the
addition of 0.25% trypsin/EDTA, split, and partitioned into
additional 75 cm2 flasks.
2.2. Human Bone-Marrow-Derived MSC Adipocyte Differentiation. MSCs (passages 2-3) were plated in 75 cm2 flasks
and 24-well plates at a density of 1-2 × 104 cells per cm2 and
were again cultured in their respective maintenance media
until cells were 80% confluent. The maintenance medium was
then replaced with adipogenic medium and the cells were
cultured for an additional 14 days. The adipogenic medium
consisted of complete culture medium supplemented with
DMEM-high glucose (Invitrogen, Carlsbad, CA), 10% FBS,
1% A/A, 10 𝜇g/mL insulin, 1 𝜇M dexamethasone (SigmaAldrich, St. Louis, MO), and 0.1 mM Indomethacin (SigmaAldrich, St. Louis, MO). Human MSCs were cultured in
this adipogenic differentiation medium along with fructose
and uric acid in the presence and absence of the HO-1
inducer cobalt protoporphyrin (CoPP) (5 𝜇M), HO activity
inhibitor tin-mesoporphyrin (SnMP) (5 𝜇M), xanthine oxidase inhibitor allopurinol (50 𝜇M) (Sigma-Aldrich, St. Louis,
MO), and NADPH oxidase inhibitor apocynin (100 𝜇M)
(Sigma-Aldrich, St. Louis, MO). The medium and treatments
were renewed daily.
2.3. Fructose and Uric Acid Concentrations on Adipogenesis.
To determine the optimal effect of fructose and uric acid
on MSC-derived adipocyte differentiation, cells were treated
with fructose at concentrations of 500 and 1000 𝜇M/L and
uric acid at concentrations of 5 and 10 mg/dL, respectively.
After 14 days, cells were stained with Oil Red O solution.
Optimum concentrations for fructose and uric acid were
found to be 500 𝜇M/L and 5 mg/dL, respectively. These concentrations were utilized during treatment of cells throughout
experimentation.
2.4. Oil Red O Staining. 0.21% Oil Red O in 100% isopropanol
(Sigma-Aldrich, St. Louis, MO) was used for staining. Briefly,
adipocytes were fixed in 4% formaldehyde, stained with Oil
Red O for 10 min, and rinsed with pH 7.2 PBS (1x) (Invitrogen,
Carlsbad, CA). Pictures were captured using an Olympus
IX81 Motorized Inverted Microscope. Oil Red O was eluted
by adding 100% isopropanol for 10 min and OD was measured
at 490 nm 24 hours later.

2. Material and Methods

2.5. Measurement of Lipid Droplet Size. Cell size was measured using ImagePro Analyzer (Media Cybernetics, Inc.,
MD). The classification of the size of lipid droplets was based
on size by area (pixels).

2.1. Human Bone-Marrow-Derived MSC Culture. Frozen
bone marrow mononuclear cells were purchased from All
Cells (Emeryville, CA). After thawing, mononuclear cells
(MSCs) were resuspended in 𝛼-minimal essential medium

2.6. Measurement of MSC-Derived Adipocyte Signaling Molecules. Cells were maintained at −80∘ C until required for
assay. Frozen cells were pulverized and placed in a homogenization buffer (10 mM phosphate buffer, 250 mM sucrose,
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Figure 1: (a) Adipogenesis as shown by Oil Red O staining in MSCs treated with 500 𝜇M and 1000 𝜇M fructose. A representative section for
each group is shown. (b) Adipogenesis as shown by Oil Red O staining in MSCs treated with 500 𝜇M fructose with or without CoPP, in the
presence or absence of SnMP, magnifications: 40x (𝑛 = 5). A representative section for each group is shown. Values represent means ± SEM
of five independent treatments. ∗ 𝑝 < 0.05 versus CTR; # 𝑝 < 0.05 versus Fr; and + 𝑝 < 0.05 versus Fr + CoPP.

1 mM EDTA, 0.1 mM PMSF, and 0.1% Tergitol, pH 7.5).
Homogenates were centrifuged at 10,000 rpm for 10 minutes
at 4∘ C. The supernatant was isolated and protein levels were
assayed (Bradford method). The supernatant was used for
measurement of XO, NADPH oxidase, and 𝛽-actin levels.
𝛽-actin was used to ensure adequate sample loading for all
western blots.
2.7. Measurement of Superoxide Levels. MSC-derived adipocytes were cultured on 96-well plates until they achieved
approximately 70% confluence. After treatment with or without uric acid (5 mg/dL) in the absence and presence of CoPP
(5 𝜇M) and SnMP (5 𝜇M) for 2 days, the cells were incubated
with 10 𝜇M dihydroethidium (DHE) for 30 min at 37∘ C.
Fluorescence intensity was measured using a Perkin-Elmer
Luminescence Spectrometer at excitation/emission filters of
530/620 nm.
2.8. RNA Extraction and Real-Time PCR Experiments. Total
RNA was extracted from MSC-derived adipocytes using
RNeasy Protect Mini kit (QIAGEN, MD, USA) according to
the manufacturer’s instructions. Total RNA (1 𝜇g) was transcribed into cDNA using GeneAmp kit (Applied Biosystems,
Branchburg, NJ, USA) reverse transcription reagents. Total
RNA was analyzed by a quantitative real-time polymerase
chain reaction (qRT-PCR). Real-time PCR was performed
using SYBR Green PCR Master Mix (Applied Biosystems) on
a 7500 HT Fast Real-Time PCR System (Applied Biosystems).
Specific primers used were HO-1, PPAR𝛾, FAS, C/EBP𝛼,
Wnt10b, Mest, and actin. Each reaction was performed in
triplicate. The comparative threshold cycle (Ct) method was
used to calculate the fold amplification as specified by the
manufacturer. All experimental samples were normalized

using GAPDH as an internal control and normalization was
performed in separate reactions.
2.9. Statistical Analyses. Statistical significance was determined using one-way analysis of variance followed by TukeyKramer post hoc test. 𝑝 < 0.05 was considered to be
significant. Data are expressed as means ± standard error of
the mean (SEM).

3. Results
3.1. Effect of Fructose on Adipogenesis in MSC-Derived
Adipocytes. We measured adipogenesis in MSC-derived
adipocytes after treatment with increasing concentrations
of fructose. Fructose at a concentration of 500 𝜇M/L was
determined to be the optimal concentration for stimulating
adipogenesis in MSC-derived adipocytes as compared to the
control (Figure 1(a); 𝑝 < 0.05) as shown by us previously
[27]. The same instrumental analysis was applied to MSCderived adipocytes being treated with CoPP, an HO-1 agonist,
which showed a reduction in adipogenesis to levels similar to
the control group. When SnMP, an HO-1 activity inhibitor,
was added to cells treated with both fructose and CoPP,
adipogenesis increased to levels seen with only fructose
treatment (Figure 1(b); 𝑝 < 0.05).
3.2. Effect of HO-1 Induction on XO and Uric Acids Levels
in MSC-Derived Adipocytes. Fructose metabolism invokes
the consumption of ATP and thereby increases intracellular
activity of XO and its product, uric acid. In concordance
with our hypothesis, our results showed that fructose treatment of MSC-derived adipocytes significantly increased XO
expression and uric acid to levels higher than the control
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Figure 2: (a) XO expression by western blot analysis. Data are shown as mean band density normalized to 𝛽-actin. Results are means ± SE,
𝑛 = 4/group. ∗ 𝑝 < 0.05 versus CTR; # 𝑝 < 0.05 versus Fr; and + 𝑝 < 0.05 versus Fr + CoPP. (b) Measurement of uric acid levels in pelleted cells
at day 14 of adipogenesis in human MSCs treated with 500 𝜇M fructose with or without CoPP, in the presence or absence of SnMP. Values
represent means ± SEM of five independent treatments. ∗ 𝑝 < 0.05 versus CTR; # 𝑝 < 0.05 versus Fr; and + 𝑝 < 0.05 versus Fr + CoPP.

(Figures 2(a) and 2(b), resp.; 𝑝 < 0.05). Concurrent treatment
with fructose and CoPP effectively reversed both XO and uric
acid levels to that of the control (𝑝 < 0.05). The addition of
SnMP negated the beneficial effects of CoPP and increased
XO and uric acid levels.
3.3. Effect of Uric Acid on Adipogenesis in MSC-Derived
Adipocytes. We studied whether uric acid might be mediating fructose-induced adipogenesis. A concentration curve
was obtained by treating cultured MSCs with uric acid
concentrations of 5 mg/dL and 10 mg/dL. We demonstrated
that cells treated with uric acid at a concentration of 5 mg/dL
showed the maximum adipogenesis as compared to the
control (Figure 3(a); 𝑝 < 0.05). After observing an increase
in adipogenesis in cells treated with uric acid, we then treated
MSCs concurrently with uric acid and CoPP to confirm
that HO-1 decreased uric acid-mediated adipogenesis. CoPP
administration was shown to negate the adipogenic effect
of uric acid and reduce adipogenesis to that of the control
(Figure 3(b); 𝑝 < 0.05). Our results further showed that
SnMP, an HO activity inhibitor, reversed the beneficial effect
of CoPP, resulting in increased adipogenesis (Figure 3(b);
𝑝 < 0.05).
3.4. Effect of Uric Acid on Lipid Droplet Size and Mest and
FAS Levels in MSC-Derived Adipocytes. The number of large,
inflamed lipid droplets and small, healthy lipid droplets were
measured in cells treated with uric acid (Figure 4(a)). Uric
acid was shown to increase the number of large lipid droplets
(Figure 4(b)) and decrease the number of small droplets as

compared to the control (Figure 4(c); 𝑝 < 0.05). However,
the concurrent administration of CoPP completely reversed
this effect and decreased large droplets and increased small
droplets when compared to control (𝑝 < 0.05). Concurrent
treatment with SnMP reversed the beneficial effects of CoPP
and the number of large lipid droplets was measured to be
higher than that of the control (Figure 4(a); 𝑝 < 0.05).
Furthermore, our results showed that uric acid increased
Mest and FAS expression levels compared to the control
(Figures 4(d) and 4(e), resp.; 𝑝 < 0.05). CoPP reversed the
effects of uric acid and decreased Mest and FAS expression as
compared to the cells treated with uric acid alone.
3.5. Effect of Uric Acid on HO-1 and Adipogenic Markers in
MSC-Derived Adipocytes. Uric acid reduced expression of
Wnt10b but had no effect on HO-1 expression. The effects
of uric acid were reversed upon addition of CoPP, which
increased HO-1 and Wnt10b expression to levels above the
control (Figures 5(a) and 5(b), resp.; 𝑝 < 0.05). When
these MSCs were treated with the combination of uric acid,
CoPP, and SnMP, the expression of Wnt10b was reduced
to that of control. HO-1 expression remained unchanged as
expected, given that SnMP modifies HO-1 activity and not its
expression.
The expression of C/EBP𝛼 and PPAR𝛾, known mediators
of adipocyte hypertrophy, were also measured by RT-PCR.
Treatment of MSCs with uric acid increased expression of
both C/EBP𝛼 and PPAR𝛾 (Figures 5(c) and 5(d), resp.; 𝑝 <
0.05), and the levels of these proadipogenic mediators were
reduced with addition of CoPP. When SnMP was added to
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Figure 3: (a) Adipogenesis as shown by Oil Red O staining in MSCs treated with 5 mg/dL and 10 mg/dL uric acid. A representative section
for each group is shown. (b) Adipogenesis as shown by Oil Red O staining in MSCs treated with 5 mg/dL uric acid with or without CoPP, in
the presence or absence of SnMP, magnifications: 40x (𝑛 = 5). A representative section for each group is shown. Values represent means ±
SEM of five independent treatments. ∗ 𝑝 < 0.05 versus CTR; # 𝑝 < 0.05 versus UA; and + 𝑝 < 0.05 versus UA + CoPP.

MSCs treated with uric acid and CoPP, the protective factor
of HO-1 was eliminated and the expression levels of PPAR𝛾
and C/EBP𝛼 significantly increased as compared to the cells
treated with uric acid and CoPP alone.
3.6. Effect of Uric Acid on Oxidative Stress in MSC-Derived
Adipocytes. In order to better understand the mechanism
by which uric acid was inducing adipogenesis and whether
HO-1 induction plays an important role in attenuating
uric acid-induced adipogenesis, NADPH oxidase expression and superoxide levels were measured. In MSC-derived
adipocytes treated with uric acid, NADPH oxidase significantly increased compared to the control (Figure 6(a); 𝑝 <
0.05). Similarly, superoxide levels were elevated in MSCderived adipocytes treated with uric acid (Figure 6(b); 𝑝 <
0.05). This oxidative stress was predicted to be an important
cause of adipocyte dysfunction, so we treated cells with
both uric acid and CoPP to see if HO-1 could decrease
adipogenesis. Our results showed that CoPP significantly
suppressed NADPH oxidase expression and superoxide levels
as compared to cells treated with uric acid alone (𝑝 < 0.05).
This positive outcome was effectively reversed by the addition
of SnMP.
3.7. Inhibition of Fructose-Mediated Adipogenesis with Allopurinol and Uric Acid-Mediated Adipogenesis with Apocynin.
First we sought to compare the effects on adipogenesis of
CoPP and allopurinol, a known antagonist of XO. MSCderived adipocytes were exposed to either fructose and
allopurinol (100 mM) or fructose and CoPP, and adipogenesis
was measured. Our results showed that allopurinol and CoPP
attenuated adipogenesis at similar levels (Figure 7(a)). Then

we sought to compare the effects on adipogenesis of CoPP
and apocynin (500 mM), a known inhibitor of NADPH
oxidase. In a similar fashion, MSC-derived adipocytes were
treated with the combination of uric acid and apocynin or
uric acid and CoPP. Adipogenesis was inhibited in both
treatment groups when compared to control (𝑝 < 0.05), and
the magnitude of inhibition was relatively equal (Figure 7(b)).

4. Discussion
This study demonstrates the stimulatory effect of exogenous uric acid on adipogenesis in MSC-derived adipocytes,
confirming their proadipogenic effects and the positive link
between uric acid and the occurrence of obesity. This uric
acid-mediated adipogenesis is attenuated by the induction of
HO-1, suggesting its beneficial role in improving adipocyte
function and decreasing XO and NADPH oxidase levels,
thereby decreasing oxidative stress. The effects of uric acid
were accompanied by increases in the proadipogenic factors
Mest, FAS, C/EBP𝛼, and PPAR𝛾, as well as decreases in the
antiadipogenic factor Wnt10b; these findings are significantly
reversed by treatment with CoPP. Thus, hyperuricemia stands
as a potential contributing agent to obesity, and augmentation
of HO-1 offers a promising avenue in attenuating adipocyte
dysfunction.
Using MSCs as our study vehicle, we demonstrated that
administration of either fructose or uric acid induced an
increase in the amount of adipogenesis as compared to the
control. These results verify that fructose and uric acid both
have proadipogenic effects. Further our data demonstrated
that MSC-derived adipocytes treated with uric acid produced
a decreased expression of Wnt10b, which is essential in
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Figure 4: (a–c) Number of large and small lipid droplets from Oil Red O stained MSCs with 5 mg/dL uric acid with or without CoPP, in the
presence or absence of SnMP; magnifications: 40x (𝑛 = 3). A representative section for each group is shown. Values represent means ± SEM
of five independent treatments. ∗ 𝑝 < 0.05 versus CTR; # 𝑝 < 0.05 versus UA; and + 𝑝 < 0.05 versus UA + CoPP. (d) Real-time PCR of Mest. (e)
and (d) Real-time PCR of FAS expression in MSCs treated with uric acid with or without CoPP, in the presence or absence of SnMP. Values
represent means ± SEM of five independent treatments. ∗ 𝑝 < 0.05 versus CTR; # 𝑝 < 0.05 versus UA; and + 𝑝 < 0.05 versus UA + CoPP.

the activation of the canonical pathway and inhibition of
adipogenesis [28, 29]. We also showed increased expression of C/EBP-𝛼 and PPAR𝛾, which has a crucial role in
the transcriptional regulation of the adipocyte gene [21].
Moreover, our results showed that uric acid increased Mest
expression, which is an important marker for enlargement of
adipocytes during adipose tissue expansion [30]. Adipocyte
enlargement is associated with an increase in the levels of
inflammatory cytokines and oxidative stress [20, 24]. The
morphologic changes induced by fructose and uric acid to the
MSC-derived adipocytes support the link between excessive
fructose intake and obesity.

Our results demonstrated that HO-1 induction attenuated
adipogenesis induced by uric acid and fructose in MSCderived adipocytes. One process by which fructose has been
postulated to fuel such an increase in adipogenesis is the
aforementioned unregulated ATP-dependent phosphorylation of fructose and subsequent buildup of uric acid via the
purine degradation pathway [30]. Support for this theory
stems from the result that uric acid, like fructose, is also
proadipogenic. Since uric acid exerts its effects through ROS,
HO-1, a potent antioxidant, was explored as a method of
treatment. Induction of HO-1 decreases adipogenesis via
suppression of transcription factors, including PPAR𝛾, aP2,
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Figure 5: Real-time PCR of (a) HO-1; (b) Wnt10b; (c) C/EBP𝛼; and (d) PPAR𝛾 expression in MSCs treated with uric acid with or without
CoPP, in the presence or absence of SnMP. Values represent means ± SEM of five independent treatments. ∗ 𝑝 < 0.05 versus CTR; # 𝑝 < 0.05
versus UA; and + 𝑝 < 0.05 versus UA + CoPP.
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Figure 6: (a) NADPH oxidase expression by western blot analysis. Data are shown as mean band density normalized to 𝛽-actin. Results are
means ± SE, 𝑛 = 4/group. ∗ 𝑝 < 0.05 versus CTR; # 𝑝 < 0.05 versus UA; and + 𝑝 < 0.05 versus UA + CoPP. (b) Measurement of superoxide
levels in pelleted cells at day 14 of adipogenesis in human MSCs treated with 5 mg/dL uric acid with or without CoPP, in the presence or
absence of SnMP. Values represent means ± SEM of five independent treatments. ∗ 𝑝 < 0.05 versus CTR; # 𝑝 < 0.05 versus UA; and + 𝑝 < 0.05
versus UA + CoPP.
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Figure 7: (a) Adipogenesis as shown by Oil Red O staining in MSCs treated with 500 𝜇M fructose with or without CoPP and with or without
allopurinol, a known inhibitor of XO. A representative section for each group is shown; ∗ 𝑝 < 0.05 versus CTR; # 𝑝 < 0.05 versus Fr. (b)
Adipogenesis as shown by Oil Red O staining in MSCs treated with 5 mg/dL uric acid with or without CoPP and with or without apocynin, a
known inhibitor of NADPH oxidase, magnifications: 40x (𝑛 = 5). A representative section for each group is shown. Values represent means
± SEM of five independent treatments. ∗ 𝑝 < 0.05 versus CTR; # 𝑝 < 0.05 versus UA.

and Mest proteins, while concomitantly increasing Wnt10b
and adiponectin levels [25, 26, 28, 29, 31, 32]. We demonstrated in our study that upregulation of HO-1 counteracts
the increase in adipogenesis resulting from treatment with
fructose or uric acid in MSCs-derived adipocytes and also
decreased adipocyte size, whereas inhibition of HO activity
by SnMP increased adipocyte dysfunction. Our data further
showed that the induction of HO-1 suppressed adipocyte
differentiation, as evidenced by an increase in the canonical
Wnt cascade and a decrease in Peg-1/Mest, FAS, and PPAR𝛾
in uric acid-treated cells.
This study showed that induction of HO-1 via CoPP
reduced expression of XO and NADPH oxidase and
decreased oxidative stress-mediated adipogenesis in MSCderived adipocytes. Uric acid produced in the presence of
fructose via the upregulation of xanthine oxidase leads to
an increase in oxidative stress. Our results showed for the
first time that the MSC-derived adipocytes treated with
fructose and CoPP downregulated XO expression. HO-1
induction also decreased uric acid levels, the final product
of XO, further suggesting the beneficial role of HO-1 in
attenuating XO-mediated oxidative stress and adipogenesis.
Another potential mechanism by which HO-1 upregulation
decreases adipogenesis in MSC-derived adipocytes may be
related to suppression of NADPH oxidase, which contributes
to oxidative stress. Bilirubin, a product of HO-1 catabolism,
has been shown to scavenge ROS and play a role in the
inhibition of NADPH oxidase [27]. Our results showed

that uric acid increased expression of NADPH oxidase in
MSC-derived adipocytes, and concurrent administration of
CoPP decreased its expression, suggesting that upregulation
of HO-1 attenuates NADPH oxidase-mediated adipogenesis.
NADPH oxidase also had the effect of upregulating the transcriptional factor Peg-1/Mest through the generation of the
superoxide ion [33]. In concordance with these reports, our
results showed that uric acid treatment in MSCs increased
expression of Peg-1/Mest, and upregulation of HO-1 negated
this increase in Peg-1/Mest expression. To further confirm
our hypothesis that HO-1 upregulation plays an important
role in attenuating XO- and NADPH oxidase-mediated adipogenesis, the efficacy of HO-1 was established by comparing
its effect on adipogenesis to known antagonists of XO and
NADPH oxidase, allopurinol and apocynin, respectively. Our
results demonstrated that HO-1 induction displayed similar
efficacy to that of both allopurinol and apocynin in terms
of suppressing adipogenesis. These observations indicate that
induction of HO-1 plays an important role in the prevention
of adipocyte hypertrophy and the promotion of smaller
healthier adipocytes in MSCs, in large part, through reduced
expression of XO and NADPH oxidase. Our data underscores
the importance of oxidative stress-induced adipocyte dysfunction as a result of uncontrolled fructose metabolism and
offers new insights into potential therapies by which targeting
fructose metabolism and/or downstream signaling of uric
acid can curtail adipogenesis.
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Figure 8: Proposed mechanism demonstrating the beneficial role of heme oxygenase 1 (HO-1) in the attenuation of adipocyte dysfunction
in mesenchymal stem cell- (MSC-) derived adipocytes. Excessive fructose consumption is accompanied by an increase in xanthine oxidase
and uric acid and a concurrent increase in cellular ROS levels. HO-1 suppresses adipocyte differentiation by increasing expression of key
regulators including Wnt10b and adiponectin and decreasing expression of adipogenic transcription factors CCAAT/enhancer binding
protein 𝛼 (C/EBP𝛼), peroxisome proliferator-activated receptor 𝛾 (PPAR𝛾), Mest, and FAS. These effects led to decrease in lipid accumulation
and increase of preadipocytes and healthy adipocytes that improve adipocyte function.

5. Conclusion
In conclusion (Figure 8), we demonstrate that fructose
increases adipogenesis in MSC-derived adipocytes. This
effect is mediated through uric acid resulting from uncontrolled fructose metabolism, leading to upregulation of XO
and NADPH oxidase. Given that obesity is correlated with
increased blood levels of uric acid, this provides a potentially
highly effective pharmacological intervention for overweight
and obese individuals. It also highlights the crucial role
of antioxidant therapy represented by HO-1 induction in
targeting metabolic syndrome and obesity resulting from
excessive fructose intake. Future research should seek to
explore how treatment with HO-1 agonists may alter body
mass index in patients suffering from obesity comorbid with
increased plasma concentrations of uric acid. Investigation
into this topic may prove to be extremely helpful in improving
the health of Western society.

Peg-1/Mest: Paternally expressed gene
1/mesoderm-specific transcript
PPAR𝛾:
Peroxisome proliferator activated
receptor gamma
ROS:
Reactive oxygen species
SnMP:
Tin mesoporphyrin IX dichloride
Wnt10b:
Wingless-type MMTV integration
site family, member 10b.
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